HUGO-Nano™ is Cyagen’s engineered mouse platform that generates fully human, developable single-domain VHH antibodies directly in vivo, with no camelid immunization and no post-discovery humanization. This webinar shows how ~15 kDa fully human VHH nanobodies reach difficult targets, including the blood–brain barrier, with data from 40+ CNS and oncology campaigns (DLL3, ANG2, CD8, TfR1), Tm >60°C developability, and multi-country FTO. Learn how these modular building blocks power bispecifics, ADCs, and CAR-T, and how to engage via discovery, licensing, or co-development.
VHH nanobodies (or single-domain antibodies) are moving from niche validation to large-indication scale, with late-stage clinical readouts and a clear shift toward multivalent and multispecific formats. Yet most VHH nanobody discovery still depends on camelid immunization followed by labor-intensive post-discovery humanization — adding time, cost, and immunogenicity risk. At the same time, conventional ~150 kDa IgGs are simply too large to reach many difficult targets, including crossing the blood–brain barrier for CNS programs.
This webinar introduces HUGO-Nano™, Cyagen’s engineered mouse platform that generates fully human, developable single-domainVHH antibodies directly in vivo — with no camelid immunization and no separate humanization step. By pairing a humanized VHH framework with retained camelid hallmark residues, HUGO-Nano delivers human-like low immunogenicity alongside the solubility, thermostability, and autonomous single-domain behavior that make VHHs useful as modular drug-development building blocks.
Drawing on validation across 40+ CNS and oncology discovery campaigns, the session walks through how the platform works — from a humanized VHH-style locus through standard mouse immunization, in vivo affinity maturation, and binder recovery — and presents concrete data. Highlights include anti-DLL3 leads reaching picomolar-to-nanomolar affinity with human/mouse/monkey cross-reactivity and >95% purity; anti-ANG2 binders matching benchmark potency while improving specificity; anti-CD8 nanobodies for in vivo CAR-T; and fully human TfR1 nanobodies engineered for receptor-mediated brain delivery. We also cover developability (Tm generally >60°C, controlled profiles under stress testing) and freedom-to-operate confirmed in China, the U.S., Japan, and Europe.
Finally, we show how compact HUGO-Nano building blocks reformat into bispecifics and multispecifics, T-cell engagers, ADCs, in vivo CAR-T, and radioligand/imaging formats — and outline flexible engagement models spanning fee-for-service discovery, asset licensing, and co-development.
By ticking this box, you consent to receiving communications from Cyagen related to this topic and other products or services within their portfolio